Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma
Brief Summary: RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether undergoing immediate surgery or surgery after sunitinib malate is more effective in treating patients with metastatic kidney cancer.

PURPOSE: This randomized phase III trial is studying immediate surgery to see how well it works compared with surgery after sunitinib malate in treating patients with metastatic kidney cancer.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
B: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
C: Arm Label: Lenvatinib 18 mg plus Everolimus 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Lenvatinib 20 mg plus Pembrolizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Arm Label: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg, Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib 50 mg
D: Arm Label: Immediate nephrectomy; Type: ACTIVE_COMPARATOR; Interventions: Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis, Procedure: therapeutic conventional surgery | Arm Label: Deferred nephrectomy; Type: EXPERIMENTAL; Interventions: Procedure: timing of surgery, Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis | Intervention Type: PROCEDURE; Name: timing of surgery; Assigned to Arm(s): Deferred nephrectomy | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: OTHER; Name: biologic sample preservation procedure; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): Immediate nephrectomy

Answer: D